NatWest Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

NatWest Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4,540	Closed	-$753K	–	359
2015 Q3	$753K	Buy	+4,540	New	+$999K	0.02%	218
2015 Q2	–	Sell	-4,540	Closed	-$1.28M	–	439
2015 Q1	$1.28M	Buy	4,540 +1,941	+75%	+$420K	0.02%	201
2014 Q4	$405	Buy	+2,599	New	+$480K	﹤0.01%	336

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NatWest Group's ICPT Position: Q4 2015 in Review

NatWest Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2015, closing a stake of 4,540 shares — an estimated $753K sold.

NatWest Group first reported a position in ICPT in Q4 2014 and held it in 3 quarters. The position peaked at $1.28M in Q1 2015. 172 funds tracked by Wall St. Rank hold ICPT as of Q4 2015.

NatWest Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 4,540 Intercept Pharmaceuticals, Inc. shares in Q4 2015, an estimated $753K.
NatWest Group first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 3 quarters.
NatWest Group's Intercept Pharmaceuticals, Inc. position peaked at $1.28M in Q1 2015.
172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.